23-Mar-2026
Shenwan Hongyuan Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)
TipRanks (Thu, 19-Mar 1:45 AM ET)
Business Wire (Tue, 17-Mar 4:35 PM ET)
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Business Wire (Thu, 26-Feb 7:00 AM ET)
Business Wire (Tue, 10-Feb 8:30 AM ET)
Business Wire (Tue, 13-Jan 8:00 AM ET)
Business Wire (Tue, 6-Jan 7:30 AM ET)
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
Business Wire (Mon, 5-Jan 7:30 AM ET)
Zai Lab Advances Global Pipeline as Q3 Revenue Climbs 14% and Operating Loss Narrows
Market Chameleon (Thu, 6-Nov 3:38 AM ET)
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Zai Lab Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol ZLAB.
As of March 23, 2026, ZLAB stock price declined to $17.61 with 1,545,177 million shares trading.
ZLAB has a beta of 1.19, meaning it tends to be more sensitive to market movements. ZLAB has a correlation of 0.13 to the broad based SPY ETF.
ZLAB has a market cap of $1.97 billion. This is considered a Small Cap stock.
Last quarter Zai Lab Limited - American Depositary Shares reported $128 million in Revenue and -$.46 earnings per share. This beat revenue expectation by $6 million and missed earnings estimates by -$.03.
In the last 3 years, ZLAB traded as high as $44.34 and as low as $13.48.
The top ETF exchange traded funds that ZLAB belongs to (by Net Assets): IBB, CANC, SBIO, BBP, DFEM.
ZLAB has underperformed the market in the last year with a price return of -52.8% while the SPY ETF gained +17.9%. However, in the short term, ZLAB had mixed performance relative to the market. It has outperformed in the last 3 months, returning -2.4% vs -3.4% return in SPY. But in the last 2 weeks, ZLAB shares have been beat by the market, returning -9.9% compared to an SPY return of -2.3%.
ZLAB support price is $17.49 and resistance is $18.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZLAB shares will trade within this expected range on the day.